AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical program to an adjunct approach—for now.
AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure Read More »
